Sale

Cholera Vaccines Market

Global Cholera Vaccines Market Share, Size, Forecast: By Product: Dukoral, Shanchol, Vaxchora, Euvichol, Others; By End User: Hospitals & Clinics, Research and Academic Laboratories, Others; Regional Analysis; Market Dynamics: Market Drivers and Constraints, SWOT Analysis; Supplier Landscape; 2024-2032

Global Cholera Vaccines Market Outlook

The global cholera vaccines market size attained a value of USD 120.62 million in 2023, driven by growing demand for Dukoral. The market is anticipated to grow at a CAGR of 12% during the forecast period of 2024-2032 to attain a value of USD 334.50 million by 2032.

 

Growing Demand for Dukoral to Aid the Market Growth of Cholera Vaccines

Based on product, Dukoral is predicted to hold a significant share of the market. The increasing demand for the product can be attributed to the fact that Dukoral is the only oral (drinkable) vaccine available in the market, which provides protection against cholera and diarrhoea caused by Enterotoxigenic E. coli (ETEC), the most common cause of diarrhoea for travellers to many parts of the world. This factor is contributing to the growth of the segment.

 

Global Cholera Vaccines Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Further, Dukoral can be given to adults and children 2 years of age and older. Apart from this, the growing population in the cholera endemic region as well as the individuals travelling to the said region are also anticipated to propel the segment growth in the coming years.

 

The Asia Pacific to Provide Lucrative Opportunities for the Market Expansion of Cholera Vaccines

The Asia Pacific region is estimated to hold a substantial share of the global cholera vaccines market in the forecast period. This growth can be attributed to the increasing prevalence of cholera in the region. In addition, the increased government investments supporting the immunisation process are also anticipated to propel the market growth in the forecast period. Moreover, the growing awareness pertaining to the vaccines and the increased availability of oral vaccines in the region are also predicted to bolster the market growth in the coming years. The adoption of water, sanitation, and hygiene practices has proven to be effective in protecting the population, along with the use of oral cholera vaccines (OCVs).

Meanwhile, the demand for cholera vaccines in North America is also expected to witness a considerable growth over the forecast period owing to the increased government expenditure on immunisation programmes in the region. The increasing number of travellers in North American countries, including the United States and Canada, are significantly contributing to the rising vaccine demands. In June 2016, the Food and Drug Administration (FDA) approved Vaxchora (PaxVax, Inc.) for United States (US) travellers, as no cholera vaccine was available to help protect them until that time. Vaxchora™ (CVD 103-HgR), an oral live attenuated vaccine, is the first and only cholera vaccine available in the United States.

 

Cholera Vaccines: Market Segmentation

Cholera refers to an acute diarrhoeal illness, which is caused by an infection in the intestine. It is spread through the ingestion of water or food that is contaminated with the bacterium Vibrio cholerae. An estimated number 1.3 to 4.0 million cases of cholera are reported every year, with 21,000 to 1,43,000 deaths worldwide due to cholera. The cholera vaccines are essential in controlling the spread of cholera, which is recommended by the WHO for individuals travelling to cholera affected regions, as well as people residing in such areas.

 

Global Cholera Vaccines Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

By product, the cholera vaccines market is divided into:

  • Dukoral 
  • Shanchol
  • Vaxchora
  • Others

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Rising Incidences of Cholera to Drive the Market Growth of Cholera Vaccines

According to the WHO statistics, an estimated 1.3 to 4.0 million cases of cholera are reported every year. The disease impacts children as well as adults and can result in death, if left untreated. Cholera is linked to the decreased availability of clean water and sanitation facilities. In this regard, the WHO Global Task Force on Cholera Control (GTFCC), a programme aimed at controlling the spread of cholera by 2030, was launched to reduce the mortality risk associated with the disease by 90% in cholera prone areas such as Asia and Africa. This is leading to the increased demand for cholera vaccines around the globe. In addition, rising investments by the governments to develop efficient vaccines to treat cholera are expected to further propel the cholera vaccines market forward. As cholera is a public health threat, the governments are making significant investments to provide improved water and sanitation facilities to the least privileged population, that remains largely affected by the disease due to poor sanitation. Moreover, the increasing concerns associated with cholera outbreaks and the emergence of new strains that might be of greater severity are leading to a rise in research and development activities by both government and private bodies. These factors are anticipated to positively impact the market growth in the forecast period.

 

Global Cholera Vaccines Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Key Players in the Global Market for Cholera Vaccines

The report gives a detailed analysis of the following key players in the global cholera vaccines market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Sanofi-aventis Groupe
  • Emergent BioSolutions Inc.
  • Valneva SE
  • GlaxoSmithKline plc.
  • Intervet Inc.
  • EuBiologics Co., Ltd.
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model and SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Product
  • End User
  • Region
Breakup by Product
  • Dukoral
  • Shanchol
  • Vaxchora
  • Euvichol
  • Others
Breakup by End User
  • Hospitals & Clinics
  • Research and Academic Laboratories
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Sanofi-aventis Groupe
  • Emergent BioSolutions Inc.
  • Valneva SE
  • GlaxoSmithKline plc.
  • Intervet Inc.
  • EuBiologics Co., Ltd.
  • Astellas Pharma Inc.
  • Celldex Therapeutics.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Cholera Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Cholera Vaccine Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Cholera Epidemiology (2016-2031)
    5.3    Europe Cholera Epidemiology (2016-2031)
    5.4    Asia-Pacific Cholera Epidemiology (2016-2031)
    5.5    Latin America Cholera Epidemiology (2016-2031)
    5.6    Middle East & Africa Cholera Epidemiology (2016-2031)
6    Global Cholera Vaccine Market Overview 
    6.1    Global Cholera Vaccine Market Historical Value (2017-2023)
    6.2    Global Cholera Vaccine Market Forecast Value (2024-2032)
7    Global Cholera Vaccine Market Landscape
    7.1    Cholera Vaccine: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Cholera Vaccine: Product Landscape
        7.2.1    Analysis by Product
        7.2.2    Analysis by End User
8    Cholera Vaccine Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Cholera Vaccine Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Global Cholera Vaccine Market Segmentation
    11.1    Global Cholera Vaccine Market by Product
        11.1.1    Market Overview
        11.1.2    Dukoral
        11.1.3    Shanchol
        11.1.4    Vaxchora
        11.1.5    Euvichol
        11.1.6    Others
    11.2    Global Cholera Vaccine Market by End User
        11.2.1    Market Overview
        11.2.2    Hospitals & Clinics
        11.2.3    Research and Academic Laboratories
        11.2.4    Others
    11.3    Global Cholera Vaccine Market by Region
        11.3.1    Market Overview
        11.3.2    North America
        11.3.3    Europe 
        11.3.4    Asia Pacific
        11.3.5    Latin America
        11.3.6    Middle East and Africa
12    North America Cholera Vaccine Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Cholera Vaccine Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Cholera Vaccine Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Cholera Vaccine Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Cholera Vaccine Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation 
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization 
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Partnership and Collaborations Analysis
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    Sanofi-aventis Groupe
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Emergent BioSolutions Inc.
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Valneva SE
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    GlaxoSmithKline plc.
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    Intervet Inc.
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    EuBiologics Co., Ltd.
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Astellas Pharma Inc.
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Celldex Therapeutics.
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Johnson & Johnson Services Inc.
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    Merck & Co. Inc.
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
24    Cholera Vaccine - Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

Globally, cholera vaccines market reached a value of USD 120.62 million in 2023.

The market is projected to expand at a CAGR of 12% from 2024 to 2032, growing to USD 334.50 million by 2032.

The major drivers of the industry, such as the increased demand for cholera vaccines in the cholera endemic region, growing pharmaceutical industry, rising demand for cholera vaccines for travellers, and the rising incidences of cholera, are expected to aid the market growth.

The key market trends guiding the growth of the industry include the rising investments in research and development of vaccines by the leading life sciences companies.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The significant products considered in the market report include Dukoral, Shanchol, Vaxchora, and others.

The major players in the industry are Sanofi-aventis Groupe, Emergent BioSolutions Inc., Valneva SE, GlaxoSmithKline plc., Intervet Inc., EuBiologics Co., Ltd., and others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER